Literature DB >> 18278528

Minimum requirements for a rapid and reliable routine identification and antibiogram of Fusobacterium necrophorum.

A Jensen1, L Hagelskjaer Kristensen, H Nielsen, J Prag.   

Abstract

Three hundred fifty-seven isolates of Fusobacterium necrophorum from human infections in Denmark were consecutively collected over a 3 year period for the purpose of establishing the minimum requirements for rapid and reliable routine identification of Fusobacterium necrophorum using phenotypic characters. The first 40 isolates were fully characterized by the most common phenotypic tests mentioned in the literature, while the last 317 where identified solely by the established minimum requirements for rapid and reliable routine identification of Fusobacterium necrophorum. All but one isolate were identical in all phenotypic tests. The outlying strain differed in morphology and the ability to agglutinate erythrocytes. On the basis of our findings it should be possible within 3-4 days to identify and differentiate F. necrophorum from other species including other Fusobacterium spp. by the unique but subspecies specific colony morphology, susceptibility to kanamycin and metronidazole, the smell of butyric acid, chartreuse colour fluorescence, and beta-haemolysis on horse blood agar. Three-hundred fifty-six isolates were identified as F. necrophorum subsp. funduliforme while one strain was F. necrophorum subsp. necrophorum. The species and subspecies level was confirmed for the first 40 isolates by real-time PCR. MIC in mg/l was determined for the 40 isolates. MIC(90) was 0.047 for penicillin, 0.047 for clindamycin, 0.25 for metronidazole, 0.38 for cefuroxime, >32 for imipenem, 0.012 for meropenem, and 2 for erythromycin. All 357 isolates were susceptible to penicillin and metronidazole indicating that these antibiotics are still the drugs of choice in antibiotic therapy of F. necrophorum infections, but therapy with clindamycin may be an alternative. Erythromycin should be avoided.

Entities:  

Mesh:

Year:  2008        PMID: 18278528     DOI: 10.1007/s10096-008-0468-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes.

Authors:  E J Goldstein; D M Citron; C Vreni Merriam; K Tyrrell; Y Warren
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Detection of Fusobacterium necrophorum subsp. funduliforme in tonsillitis in young adults by real-time PCR.

Authors:  A Jensen; L Hagelskjaer Kristensen; J Prag
Journal:  Clin Microbiol Infect       Date:  2007-04-02       Impact factor: 8.067

Review 3.  Human necrobacillosis, with emphasis on Lemierre's syndrome.

Authors:  L Hagelskjaer Kristensen; J Prag
Journal:  Clin Infect Dis       Date:  2000-09-14       Impact factor: 9.079

4.  In vitro activity of gemifloxacin (SB 265805) against anaerobes.

Authors:  E J Goldstein; D M Citron; Y Warren; K Tyrrell; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

5.  Proposal of two subspecies of Fusobacterium necrophorum (Flügge) Moore and Holdeman: Fusobacterium necrophorum subsp. necrophorum subsp. nov., nom. rev. (ex Flügge 1886), and Fusobacterium necrophorum subsp. funduliforme subsp. nov., nom. rev. (ex Hallé 1898).

Authors:  T Shinjo; T Fujisawa; T Mitsuoka
Journal:  Int J Syst Bacteriol       Date:  1991-07

6.  Classification of human and animal strains of Fusobacterium necrophorum by their pathogenic effects in mice.

Authors:  G R Smith; E A Thornton
Journal:  J Med Microbiol       Date:  1997-10       Impact factor: 2.472

7.  A comparative study of Fusobacterium necrophorum strains from human and animal sources by phenotypic reactions, pyrolysis mass spectrometry and SDS-PAGE.

Authors:  V Hall; B I Duerden; J T Magee; H C Ryley; J S Brazier
Journal:  J Med Microbiol       Date:  1997-10       Impact factor: 2.472

8.  Emergence of penicillin resistance among Fusobacterium nucleatum populations of commensal oral flora during early childhood.

Authors:  Susan Nyfors; Eija Könönen; Ritva Syrjänen; Erkki Komulainen; Hannele Jousimies-Somer
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

9.  Comparison of extracellular enzymes of Fusobacterium necrophorum subsp. necrophorum and Fusobacterium necrophorum subsp. funduliforme.

Authors:  K K Amoako; Y Goto; T Shinjo
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

10.  Lemierre's syndrome: two cases of postanginal sepsis.

Authors:  L R Lustig; B C Cusick; S W Cheung; K C Lee
Journal:  Otolaryngol Head Neck Surg       Date:  1995-06       Impact factor: 5.591

View more
  4 in total

1.  Localised Fusobacterium necrophorum infections: a prospective laboratory-based Danish study.

Authors:  L Hagelskjaer Kristensen; J Prag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-14       Impact factor: 3.267

2.  A cost-effectiveness analysis of identifying Fusobacterium necrophorum in throat swabs followed by antibiotic treatment to reduce the incidence of Lemierre's syndrome and peritonsillar abscesses.

Authors:  S Bank; K Christensen; L H Kristensen; J Prag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-11       Impact factor: 3.267

3.  Lemierre's syndrome and other disseminated Fusobacterium necrophorum infections in Denmark: a prospective epidemiological and clinical survey.

Authors:  L Hagelskjaer Kristensen; J Prag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-11       Impact factor: 3.267

4.  Early Diagnosis and Antibiotic Treatment Combined with Multicomponent Hemodynamic Support for Addressing a Severe Case of Lemierre's Syndrome.

Authors:  Andreaserena Recchia; Marco Cascella; Sabrina Altamura; Felice Borrelli; Nazario De Nittis; Elisabetta Dibenedetto; Maria Labonia; Giovanna Pavone; Alfredo Del Gaudio
Journal:  Antibiotics (Basel)       Date:  2021-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.